The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Barr, 1951, Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions, Am. J. Med., 11, 480, 10.1016/0002-9343(51)90183-0 Gordon, 1977, High density lipoprotein as a protective factor against coronary heart disease: The Framingham study, Am. J. Med., 62, 707, 10.1016/0002-9343(77)90874-9 Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation., 79, 8, 10.1161/01.CIR.79.1.8 2008, Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials, BMJ., 336, 1121, 10.1136/bmj.39548.738368.BE 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins, Lancet., 366, 1267, 10.1016/S0140-6736(05)67394-1 Hausenloy, 2008, Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels, Heart., 94, 706, 10.1136/hrt.2007.125401 Wild, 2008, Time to rethink high-density lipoprotein?, Heart., 94, 692, 10.1136/hrt.2007.126326 Hansel, 2006, One third of the variability in HDL-cholesterol level in a large dyslipidaemic population is predicted by age, sex and triglyceridaemia: The Paris La Pitie Study, Curr. Med. Res. Opin., 22, 1149, 10.1185/030079906X104821 Criqui, 1980, Cigarette smoking and plasma high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study, Circulation., 62, IV70 Hulley, 1977, Plasma high-density lipoprotein cholesterol level. Influence of risk factor intervention, JAMA., 238, 2269, 10.1001/jama.1977.03280220037017 Gnasso, 1984, Acute influence of smoking on plasma lipoproteins, Klin. Wochenschr., 62, 36 Kodama, 2007, Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis, Arch. Intern. Med., 167, 999, 10.1001/archinte.167.10.999 Rashid, 2007, Effect of obesity on high-density lipoprotein metabolism, Obesity (Silver Spring)., 15, 2875, 10.1038/oby.2007.342 Busetto, 2004, Short-term effects of weight loss on the cardiovascular risk factors in morbidly obese patients, Obesity (Silver Spring)., 12, 1256 Chahil, 2006, Diabetic dyslipidemia, Endocrinol. Metab. Clin. North Am., 35, 491, 10.1016/j.ecl.2006.06.002 Lann, 2007, Insulin resistance as the underlying cause for the metabolic syndrome, Med. Clin. North Am., 91, 1063, 10.1016/j.mcna.2007.06.012 Hayek, 1993, Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice, J. Clin. Invest., 92, 1143, 10.1172/JCI116683 Tai, 1999, Isolated low HDL cholesterol: an insulin-resistant state only in the presence of fasting hypertriglyceridemia, Diabetes., 48, 1088, 10.2337/diabetes.48.5.1088 van Leuven, 2008, Systemic inflammation as a risk factor for atherothrombosis, Rheumatology., 47, 3, 10.1093/rheumatology/kem202 Khovidhunkit, 2000, Infection and inflammation-induced proatherogenic changes of lipoproteins, J. Infect. Dis., 181, S462, 10.1086/315611 Heiss, 1980, Plasma high-density lipoprotein cholesterol and socioeconomic status. The Lipid Research Clinics Program Prevalence Study, Circulation., 62, IV108 Sapolsky, 1987, Social subordinance in wild baboons is associated with suppressed high density lipoprotein-cholesterol concentrations: the possible role of chronic social stress, Endocrinology., 121, 1605, 10.1210/endo-121-5-1605 Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA., 302, 1993, 10.1001/jama.2009.1619 Becher, 1992, The concept of residual confounding in regression models and some applications, Stat. Med., 11, 1747, 10.1002/sim.4780111308 Asztalos, 2004, High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study, Arterioscler. Thromb. Vasc. Biol., 24, 2181, 10.1161/01.ATV.0000146325.93749.a8 Kontush, 2006, Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis, Pharmacol. Rev., 58, 342, 10.1124/pr.58.3.1 Fielding, 1982, Cholesterol transport between cells and body fluids. Role of plasma lipoproteins and the plasma cholesterol esterification system, Med. Clin. North Am., 66, 363, 10.1016/S0025-7125(16)31425-0 Groen, 2001, Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL, J. Clin. Invest., 108, 843, 10.1172/JCI200112473 Alam, 2001, Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice, J. Biol. Chem., 276, 15641, 10.1074/jbc.M010230200 deGoma, 2008, Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches, J. Am. Coll. Cardiol., 51, 2199, 10.1016/j.jacc.2008.03.016 Miettinen, 1989, Cholesterol absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels, Am. J. Clin. Nutr., 49, 629, 10.1093/ajcn/49.4.629 Gylling, 1992, Non-cholesterol sterols, absorption and synthesis of cholesterol and apolipoprotein A-I kinetics in a Finnish lecithin-cholesterol acyltransferase deficient family, Atherosclerosis., 95, 25, 10.1016/0021-9150(92)90172-D Beher, 1983, Effect of blood high density lipoprotein cholesterol concentration on fecal steroid excretion in humans, Life Sci., 32, 2933, 10.1016/0024-3205(83)90643-4 El-Harchaoui, 2009, Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia, Atherosclerosis., 207, 614, 10.1016/j.atherosclerosis.2009.06.022 Eriksson, 1999, Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans, Circulation., 100, 594, 10.1161/01.CIR.100.6.594 Nanjee, 2001, Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans, J. Lipid Res., 42, 1586, 10.1016/S0022-2275(20)32212-4 Brousseau, 2005, Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion, Arterioscler. Thromb. Vasc. Biol., 25, 1057, 10.1161/01.ATV.0000161928.16334.dd Schwartz, 1978, Multicompartmental analysis of cholesterol metabolism in man. Characterization of the hepatic bile acid and biliary cholesterol precursor sites, J. Clin. Invest., 61, 408, 10.1172/JCI108952 Turner, 2005, Emerging applications of kinetic biomarkers in preclinical and clinical drug development, Curr. Opin. Drug Discov. Devel., 8, 115 Yvan-Charvet, 2007, Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL, Arterioscler. Thromb. Vasc. Biol., 27, 1132, 10.1161/ATVBAHA.106.138347 Chirinos, 2005, Ability of serum to decrease cellular acylcoA:cholesterol acyl transferase activity predicts cardiovascular outcomes, Circulation., 112, 2446, 10.1161/CIRCULATIONAHA.104.521815 Oram, 2000, ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages, J. Biol. Chem., 275, 34508, 10.1074/jbc.M006738200 Wang, 2004, ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins, Proc. Natl. Acad. Sci. USA., 101, 9774, 10.1073/pnas.0403506101 Pagler, 2006, SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux, J. Biol. Chem., 281, 11193, 10.1074/jbc.M510261200 Pirillo, 2006, 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages, Biochim. Biophys. Acta., 1761, 292, 10.1016/j.bbalip.2006.03.009 Stangl, 1998, Scavenger receptor, class B, type I-dependent stimulation of cholesterol esterification by high density lipoproteins, low density lipoproteins, and nonlipoprotein cholesterol, J. Biol. Chem., 273, 31002, 10.1074/jbc.273.47.31002 Ji, 1997, Scavenger Receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux, J. Biol. Chem., 272, 20982, 10.1074/jbc.272.34.20982 Wang, 2007, Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo, J. Clin. Invest., 117, 2216, 10.1172/JCI32057 van Dam, 2002, Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study, Lancet., 359, 37, 10.1016/S0140-6736(02)07277-X Linsel-Nitschke, 2009, Macrophage cholesterol efflux correlates with lipoprotein subclass distribution and risk of obstructive coronary artery disease in patients undergoing coronary angiography, Lipids Health Dis., 8, 14, 10.1186/1476-511X-8-14 Cockerill, 1995, High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules, Arterioscler. Thromb. Vasc. Biol., 15, 1987, 10.1161/01.ATV.15.11.1987 Navab, 1991, Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein, J. Clin. Invest., 88, 2039, 10.1172/JCI115532 Moudry, 1997, Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells, Shock., 7, 175, 10.1097/00024382-199703000-00004 Navab, 2001, HDL and the inflammatory response induced by LDL-derived oxidized phospholipids, Arterioscler. Thromb. Vasc. Biol., 21, 481, 10.1161/01.ATV.21.4.481 Lee, 2005, High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity, Atherosclerosis., 183, 251, 10.1016/j.atherosclerosis.2005.03.029 Robbesyn, F, Garcia, V, Auge, N, Vieira, O, Frisach, MF, Salvayre, R, Negre-Salvayre, A. 2003. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-κB activation in smooth muscle cells. FASEB J. 02–0240fje. Puranik, 2008, Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo, Atherosclerosis., 196, 240, 10.1016/j.atherosclerosis.2007.05.008 Nicholls, 2005, Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits, Circulation., 111, 1543, 10.1161/01.CIR.0000159351.95399.50 Ansell, 2003, Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment, Circulation., 108, 2751, 10.1161/01.CIR.0000103624.14436.4B Navab, 2001, A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids, J. Lipid Res., 42, 1308, 10.1016/S0022-2275(20)31582-0 Davies, 1986, Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro, Proc. Natl. Acad. Sci. USA., 83, 2114, 10.1073/pnas.83.7.2114 Suc, 1997, HDL and apoA prevent cell death of endothelial cells induced by oxidized LDL, Arterioscler. Thromb. Vasc. Biol., 17, 2158, 10.1161/01.ATV.17.10.2158 Sugano, 2000, High-density lipoproteins protect endothelial cells from tumor necrosis factor-[alpha]-induced apoptosis, Biochem. Biophys. Res. Commun., 272, 872, 10.1006/bbrc.2000.2877 Nofer, 2001, Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids, J. Biol. Chem., 276, 34480, 10.1074/jbc.M103782200 Kimura, 2001, Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells, J. Biol. Chem., 276, 31780, 10.1074/jbc.M104353200 Kimura, 2003, High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and Its receptors, Arterioscler. Thromb. Vasc. Biol., 23, 1283, 10.1161/01.ATV.0000079011.67194.5A Chen, 1994, Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets, Life Sci., 55, 1815, 10.1016/0024-3205(94)90092-2 Nofer, 2002, HDL and arteriosclerosis: beyond reverse cholesterol transport, Atherosclerosis., 161, 1, 10.1016/S0021-9150(01)00651-7 Griffin, 1999, High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C, J. Clin. Invest., 103, 219, 10.1172/JCI5006 Oslakovic, 2009, Anionic phospholipids lose their procoagulant properties when incorporated into high- density lipoproteins, J. Biol. Chem., 284, 5896, 10.1074/jbc.M807286200 Deguchi, 2005, High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men, Circulation., 112, 893, 10.1161/CIRCULATIONAHA.104.521344 Pomp, 2007, Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations, Br. J. Haematol., 139, 289, 10.1111/j.1365-2141.2007.06780.x Alessi, 2008, Metabolic syndrome, haemostasis and thrombosis, Thromb. Haemost., 99, 995, 10.1160/TH07-11-0682 Yuhanna, 2001, High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase, Nat. Med., 7, 853, 10.1038/89986 Nieuwdorp, 2008, Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus, Diabetologia., 51, 1081, 10.1007/s00125-008-0975-2 Spieker, 2002, High-density lipoprotein restores endothelial function in hypercholesterolemic men, Circulation., 105, 1399, 10.1161/01.CIR.0000013424.28206.8F Bisoendial, 2003, Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein, Circulation., 107, 2944, 10.1161/01.CIR.0000070934.69310.1A Russell, 2006, Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis, Cardiovasc. Pathol., 15, 318, 10.1016/j.carpath.2006.09.001 Lusis, 2007, The problem of passenger genes in transgenic mice, Arterioscler. Thromb. Vasc. Biol., 27, 2100, 10.1161/ATVBAHA.107.147918 Lichtman, 1999, Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate, Arterioscler. Thromb. Vasc. Biol., 19, 1938, 10.1161/01.ATV.19.8.1938 Plump, 1999, Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression, Arterioscler. Thromb. Vasc. Biol., 19, 1105, 10.1161/01.ATV.19.4.1105 Westerterp, 2006, Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE∗3-Leiden mice, Arterioscler. Thromb. Vasc. Biol., 26, 2552, 10.1161/01.ATV.0000243925.65265.3c Li, 1993, Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice, Arterioscler. Thromb., 13, 1814, 10.1161/01.ATV.13.12.1814 Voyiaziakis, 1998, ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice, J. Lipid Res., 39, 313, 10.1016/S0022-2275(20)33893-1 Moore, 2003, Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor, Arterioscler. Thromb. Vasc. Biol., 23, 1914, 10.1161/01.ATV.0000092328.66882.F5 Moore, 2005, Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation, Circ. Res., 97, 763, 10.1161/01.RES.0000185320.82962.F7 Nakamuta, 1998, Phenotype interaction of apobec-1 and CETP, LDLR, and apoE gene expression in mice: role of apoB mRNA editing in lipoprotein phenotype expression, Arterioscler. Thromb. Vasc. Biol., 18, 747, 10.1161/01.ATV.18.5.747 Rubin, 1991, Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI, Nature., 353, 265, 10.1038/353265a0 Plump, 1994, Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse, Proc. Natl. Acad. Sci. USA., 91, 9607, 10.1073/pnas.91.20.9607 Paszty, 1994, Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice, J. Clin. Invest., 94, 899, 10.1172/JCI117412 Liu, 1994, Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice, J. Lipid Res., 35, 2263, 10.1016/S0022-2275(20)39932-6 Tangirala, 1999, Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in Mice, Circulation., 100, 1816, 10.1161/01.CIR.100.17.1816 Benoit, 1999, Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models, Circulation., 99, 105, 10.1161/01.CIR.99.1.105 Belalcazar, 2003, Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia, Circulation., 107, 2726, 10.1161/01.CIR.0000066913.69844.B2 Lebherz, 2007, Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent, Cardiovasc. Diabetol., 6, 15, 10.1186/1475-2840-6-15 Miyazaki, 1995, Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits, Arterioscler. Thromb. Vasc. Biol., 15, 1882, 10.1161/01.ATV.15.11.1882 Duverger, 1996, Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits, Circulation., 94, 713, 10.1161/01.CIR.94.4.713 Wang, 2003, Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux, Arterioscler. Thromb. Vasc. Biol., 23, 1178, 10.1161/01.ATV.0000075912.83860.26 Aiello, 2002, Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages, Arterioscler. Thromb. Vasc. Biol., 22, 630, 10.1161/01.ATV.0000014804.35824.DA Kennedy, 2005, ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation, Cell Metab., 1, 121, 10.1016/j.cmet.2005.01.002 Out, 2008, Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1, Circ. Res., 102, 113, 10.1161/CIRCRESAHA.107.161711 Joyce, 2006, ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis, J. Biol. Chem., 281, 33053, 10.1074/jbc.M604526200 Joyce, 2002, The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice, Proc. Natl. Acad. Sci. USA., 99, 407, 10.1073/pnas.012587699 Singaraja, 2002, Increased ABCA1 activity protects against atherosclerosis, J. Clin. Invest., 110, 35, 10.1172/JCI0215748 Basso, 2006, Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet, Biochem. Biophys. Res. Commun., 351, 398, 10.1016/j.bbrc.2006.10.044 Burgess, 2008, Overexpression of human ABCG1 does not affect atherosclerosis in fat-fed ApoE-deficient mice, Arterioscler. Thromb. Vasc. Biol., 28, 1731, 10.1161/ATVBAHA.108.168542 Van Eck, 2002, Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues, Proc. Natl. Acad. Sci. USA., 99, 6298, 10.1073/pnas.092327399 Van Eck, 2006, Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice, Arterioscler. Thromb. Vasc. Biol., 26, 929, 10.1161/01.ATV.0000208364.22732.16 Curtiss, 2006, Is two out of three enough for ABCG1?, Arterioscler. Thromb. Vasc. Biol., 26, 2175, 10.1161/01.ATV.0000243741.89303.27 Jonas, 2000, Lecithin cholesterol acyltransferase, Biochim. Biophys. Acta., 1529, 245, 10.1016/S1388-1981(00)00153-0 Lambert, 2001, Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice, J. Biol. Chem., 276, 15090, 10.1074/jbc.M008466200 Furbee, 2002, Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice, J. Biol. Chem., 277, 3511, 10.1074/jbc.M109883200 Mertens, 2003, Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis, Circulation., 107, 1640, 10.1161/01.CIR.0000056523.08033.9F Berard, 1997, High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithinchoesteryl acyltransferase, Nat. Med., 3, 744, 10.1038/nm0797-744 Foger, 1999, Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice, J. Biol. Chem., 274, 36912, 10.1074/jbc.274.52.36912 Mehlum, 1997, Mice overexpressing human lecithin: cholesterol acyltransferase are not protected against diet-induced atherosclerosis, APMIS., 105, 861, 10.1111/j.1699-0463.1997.tb05095.x Mehlum, 2000, Overexpression of human lecithin:cholesterol acyltransferase in mice offers no protection against diet-induced atherosclerosis, APMIS., 108, 336, 10.1034/j.1600-0463.2000.d01-65.x Furbee, 2002, Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition, Atherosclerosis., 165, 89, 10.1016/S0021-9150(02)00201-0 Hoeg, 1996, Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis, Proc. Natl. Acad. Sci. USA., 93, 11448, 10.1073/pnas.93.21.11448 Brousseau, 1997, Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner, J. Lipid Res., 38, 2537, 10.1016/S0022-2275(20)30038-9 Brousseau, 2000, LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits, Arterioscler. Thromb. Vasc. Biol., 20, 450, 10.1161/01.ATV.20.2.450 Marotti, 1993, Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein, Nature., 364, 73, 10.1038/364073a0 Plump, 1999, Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression, Arterioscler. Thromb. Vasc. Biol., 19, 1105, 10.1161/01.ATV.19.4.1105 de Haan, 2008, Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin, Circulation., 117, 2515, 10.1161/CIRCULATIONAHA.107.761965 Herrera, 1999, Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein, Nat. Med., 5, 1383, 10.1038/70956 Hayek, 1995, Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene, J. Clin. Invest., 96, 2071, 10.1172/JCI118255 Harder, 2007, Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice, Arterioscler. Thromb. Vasc. Biol., 27, 858, 10.1161/01.ATV.0000259357.42089.dc Huang, 2002, Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia, Clin. Sci. (Lond.)., 103, 587, 10.1042/cs1030587 Okamoto, 2000, A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits, Nature., 406, 203, 10.1038/35018119 Rittershaus, 2000, Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 20, 2106, 10.1161/01.ATV.20.9.2106 Sugano, 1998, Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits, J. Biol. Chem., 273, 5033, 10.1074/jbc.273.9.5033 Morehouse, 2007, Inhibition of CETP activity by torcetrapib reduces susceptibility to diet- induced atherosclerosis in New Zealand White rabbits, J. Lipid Res., 48, 1263, 10.1194/jlr.M600332-JLR200 Acton, 1996, Identification of scavenger receptor SR-BI as a high density lipoprotein receptor, Science., 271, 518, 10.1126/science.271.5248.518 Rigotti, 1997, A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism, Proc. Natl. Acad. Sci. USA., 94, 12610, 10.1073/pnas.94.23.12610 Huby, 2006, Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues, J. Clin. Invest., 116, 2767, 10.1172/JCI26893 Braun, 2002, Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice, Circ. Res., 90, 270, 10.1161/hh0302.104462 Kozarsky, 2000, Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse, Arterioscler. Thromb. Vasc. Biol., 20, 721, 10.1161/01.ATV.20.3.721 Covey, 2003, Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells, Arterioscler. Thromb. Vasc. Biol., 23, 1589, 10.1161/01.ATV.0000083343.19940.A0 van Eck, 2004, Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development, Am. J. Pathol., 165, 785, 10.1016/S0002-9440(10)63341-X McCoy, 2002, Characterization of the lipolytic activity of endothelial lipase, J. Lipid Res., 43, 921, 10.1016/S0022-2275(20)30466-1 Ehnholm, 1975, Purification from human plasma of a heparin-released lipase with activity against triglyceride and phospholipids, J. Biol. Chem., 250, 6756, 10.1016/S0021-9258(19)40996-4 Busch, 1994, Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice, J. Biol. Chem., 269, 16376, 10.1016/S0021-9258(17)34018-8 Dichek, 2004, Divergent effects of the catalytic and bridging functions of hepatic lipase on atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 24, 1696, 10.1161/01.ATV.0000135981.61827.9d Freeman, 2007, Lipolytic and ligand-binding functions of hepatic lipase protect against atherosclerosis in LDL receptor-deficient mice, J. Lipid Res., 48, 104, 10.1194/jlr.M600321-JLR200 Gonzalez-Navarro, 2004, The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic mice, J. Biol. Chem., 279, 45312, 10.1074/jbc.M406495200 Mezdour, 1997, Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice, J. Biol. Chem., 272, 13570, 10.1074/jbc.272.21.13570 Barcat, 2006, Combined hyperlipidemia/hyperalphalipoproteinemia associated with premature spontaneous atherosclerosis in mice lacking hepatic lipase and low density lipoprotein receptor, Atherosclerosis., 188, 347, 10.1016/j.atherosclerosis.2005.11.022 Ishida, 2004, Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice, J. Biol. Chem., 279, 45085, 10.1074/jbc.M406360200 Ko, 2005, Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE−/− and LDLR−/− mice, J. Lipid Res., 46, 2586, 10.1194/jlr.M500366-JLR200 Tall, 2002, Regulation and mechanisms of macrophage cholesterol efflux, J. Clin. Invest., 110, 899, 10.1172/JCI0216391 Schuster, 2002, Accumulation of foam cells in liver X receptor-deficient mice, Circulation., 106, 1147, 10.1161/01.CIR.0000026802.79202.96 Joseph, 2002, Synthetic LXR ligand inhibits the development of atherosclerosis in mice, Proc. Natl. Acad. Sci. USA., 99, 7604, 10.1073/pnas.112059299 Levin, 2005, Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists, Arterioscler. Thromb. Vasc. Biol., 25, 135, 10.1161/01.ATV.0000150044.84012.68 Tangirala, 2002, Identification of macrophage liver X receptors as inhibitors of atherosclerosis, Proc. Natl. Acad. Sci. USA., 99, 11896, 10.1073/pnas.182199799 Schultz, 2000, Role of LXRs in control of lipogenesis, Genes Dev., 14, 2831, 10.1101/gad.850400 Grefhorst, 2002, Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles, J. Biol. Chem., 277, 34182, 10.1074/jbc.M204887200 Davies, 2008, Effects of the synthetic liver X receptor agonist T0901317 on the growth hormone and thyroid hormone axes in male rats, Endocrine., 33, 196, 10.1007/s12020-008-9067-9 Schaefer, 1980, Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease), Ann. Intern. Med., 93, 261, 10.7326/0003-4819-93-2-261 Clee, 2000, Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes, J. Clin. Invest., 106, 1263, 10.1172/JCI10727 Hovingh, 2005, Compromised LCAT function is associated with increased atherosclerosis, Circulation., 112, 879, 10.1161/CIRCULATIONAHA.105.540427 Hovingh, 2004, A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease, J. Am. Coll. Cardiol., 44, 1429, 10.1016/j.jacc.2004.06.070 Karathanasis, 1983, An inherited polymorphism in the human apolipoprotein A-I gene locus related to the development of atherosclerosis, Nature., 301, 718, 10.1038/301718a0 Miller, 2007, Do mutations causing low HDL-C promote increased carotid intima-media thickness?, Clin. Chim. Acta., 377, 273, 10.1016/j.cca.2006.10.001 Hong, 2002, Lack of association between increased carotid intima-media thickening and decreased HDL-cholesterol in a family with a novel ABCA1 variant, G2265T, Clin. Chem., 48, 2066, 10.1093/clinchem/48.11.2066 Chiesa, 2003, Apolipoprotein A-I(Milano): current perspectives, Curr. Opin. Lipidol., 14, 159, 10.1097/00041433-200304000-00007 Weibel, 2007, Wild-type apoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux, Arterioscler. Thromb. Vasc. Biol., 27, 2022, 10.1161/ATVBAHA.107.148403 Sirtori, 2008, Viability of developing CETP inhibitors, Cardiovasc. Ther., 26, 135, 10.1111/j.1527-3466.2008.00049.x Klos, 2007, Genetic determinants of HDL: monogenic disorders and contributions to variation, Curr. Opin. Cardiol., 22, 344, 10.1097/HCO.0b013e3281a8acad Edmondson, 2009, Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans, J. Clin. Invest., 119, 1042 Davey, 2003, 'Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?, Int. J. Epidemiol., 32, 1, 10.1093/ije/dyg070 Frikke-Schmidt, 2008, Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease, JAMA., 299, 2524, 10.1001/jama.299.21.2524 Johannsen, 2009, Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease, J. Clin. Endocrinol. Metab., 94, 1264, 10.1210/jc.2008-1342 Thompson, 2008, Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk, JAMA., 299, 2777, 10.1001/jama.299.23.2777 Willer, 2008, Newly identified loci that influence lipid concentrations and risk of coronary artery disease, Nat. Genet., 40, 161, 10.1038/ng.76 Kathiresan, 2008, Polymorphisms associated with cholesterol and risk of cardiovascular events, N. Engl. J. Med., 358, 1240, 10.1056/NEJMoa0706728 Staels, 1998, Mechanism of action of fibrates on lipid and lipoprotein metabolism, Circulation., 98, 2088, 10.1161/01.CIR.98.19.2088 Birjmohun, 2005, Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials, J. Am. Coll. Cardiol., 45, 185, 10.1016/j.jacc.2004.10.031 Robins, 2001, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial, JAMA., 285, 1585, 10.1001/jama.285.12.1585 Saha, 2007, The role of fibrates in the prevention of cardiovascular disease–a pooled meta-analysis of long-term randomized placebo-controlled clinical trials, Am. Heart J., 154, 943, 10.1016/j.ahj.2007.07.011 Kamanna, 2008, Nicotinic acid: recent developments, Curr. Opin. Cardiol., 23, 393, 10.1097/HCO.0b013e3283021c82 van der Hoorn, 2008, Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE∗3Leiden.CETP mice, Arterioscler. Thromb. Vasc. Biol., 28, 2016, 10.1161/ATVBAHA.108.171363 Brown, 2001, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N. Engl. J. Med., 345, 1583, 10.1056/NEJMoa011090 Taylor, 2004, Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins, Circulation., 110, 3512, 10.1161/01.CIR.0000148955.19792.8D Taylor, 2006, The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3, Curr. Med. Res. Opin., 22, 2243, 10.1185/030079906X148508 Taylor, 2009, Extended-release niacin or ezetimibe and carotid intima-media thickness, N. Engl. J. Med., 361, 2113, 10.1056/NEJMoa0907569 Lee, 2009, Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study, J. Am. Coll. Cardiol., 54, 1787, 10.1016/j.jacc.2009.06.036 Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial, JAMA., 290, 2292, 10.1001/jama.290.17.2292 Rader, 2003, High-density lipoproteins as an emerging therapeutic target for atherosclerosis, JAMA., 290, 2322, 10.1001/jama.290.17.2322 Tardif, 2007, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial, JAMA., 297, 1675, 10.1001/jama.297.15.jpc70004 Tall, 2007, CETP inhibitors to increase HDL cholesterol levels, N. Engl. J. Med., 356, 1364, 10.1056/NEJMe078029 de Grooth, 2002, Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study, Circulation., 105, 2159, 10.1161/01.CIR.0000015857.31889.7B Brousseau, 2004, Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol, N. Engl. J. Med., 350, 1505, 10.1056/NEJMoa031766 Krishna, 2007, Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies, Lancet., 370, 1907, 10.1016/S0140-6736(07)61813-3 Barter, 2007, Effects of torcetrapib in patients at high risk for coronary events, N. Engl. J. Med., 357, 2109, 10.1056/NEJMoa0706628 Bots, 2007, Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial, Lancet., 370, 153, 10.1016/S0140-6736(07)61088-5 Kastelein, 2007, Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia, N. Engl. J. Med., 356, 1620, 10.1056/NEJMoa071359 Nissen, 2007, Effect of torcetrapib on the progression of coronary atherosclerosis, N. Engl. J. Med., 356, 1304, 10.1056/NEJMoa070635 Vergeer, 2008, Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials, Circulation., 118, 2515, 10.1161/CIRCULATIONAHA.108.772665 Vergeer, 2009, The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors, Am. J. Cardiol., 104, 32E, 10.1016/j.amjcard.2009.09.017 Forrest, 2008, Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone, Br. J. Pharmacol., 154, 1465, 10.1038/bjp.2008.229 Navab, 2005, Apolipoprotein A-I mimetic peptides, Arterioscler. Thromb. Vasc. Biol., 25, 1325, 10.1161/01.ATV.0000165694.39518.95 Bloedon, 2008, Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients, J. Lipid Res., 49, 1344, 10.1194/jlr.P800003-JLR200 Navab, 2008, Apo A-1 mimetic peptides as atheroprotective agents in murine models, Curr. Drug Targets., 9, 204, 10.2174/138945008783755584 Krimbou, 2007, Abstract 679: oral administration of compound RVX-208 increases serum levels of apoA-I and improves high-density lipoprotein-mediated cholesterol efflux in african green monkeys, Circulation., 116, II 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial, JAMA., 288, 321, 10.1001/jama.288.3.321 2005, Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial, JAMA., 293, 1338, 10.1001/jama.293.11.1338 2006, Homocysteine lowering with folic acid and B vitamins in vascular disease, N. Engl. J. Med., 354, 1567, 10.1056/NEJMoa060900 Vaisar, 2007, Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL, J. Clin. Invest., 117, 746, 10.1172/JCI26206